Harpoon Therapeutics, a clinical-stage immunotherapy company engaged in the development of a class of T cell engagers, has completed a USD70m series C equity financing, it was reported yesterday.
The lead new investor is OrbiMed, along with new investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures and NS Investment. The company's present investors, MPM Capital, Oncology Impact Fund, Arix Bioscience, New Leaf Venture Partners and Taiho Ventures also participated in the Series C financing round.
The company aims to use the proceeds from the financing to support further advancement of its immunotherapy programs based on its TriTAC (Tri-specific T cell Activating Construct) and ProTriTAC (Protease-activated Tri-specific T Cell Activating Construct) platforms, which are designed to harness the natural power of the body's immune system to fight cancer and other diseases. The company's TriTAC platform was designed to advance the therapeutic potential of T cell engagers, with a long half-life extended format.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886